VCYT

Veracyte Inc

24.00

Nov 05 • 3:59 PM ET -28.52 (-54.30%)

23.90

Aftermarket • 5:00 PM ET -0.10 (-0.42%)

Healthcare Diagnostics & Research USA Small NASD

Nov 04, 7:40 PMVeracyte resets Decipher growth outlook, issues preliminary 2027 guide for mid-single-digit revenue growth and ~22% adjusted EBITDA margin after Q3 beat

Peers: MYGN NEO CSTL GH MDXH BDSX DGX NTRA GRAL TEM

| Held by: IJR XBI VTI FBT IWM ARKG VB ARKE ARKK VBK

Scroll to Statements

Index	RUT
Market Cap	1.93B
Enterprise Value	1.60B
Income	126.85M
Sales	581.78M
Book/sh	17.28
Cash/sh	4.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	755
IPO	Oct 30, 2013

P/E	15.49
Forward P/E	13.58
PEG	4.44
P/S	3.32
P/B	1.39
P/C	5.21
P/FCF	11.91
EV/EBITDA	14.13
EV/Sales	2.75
Quick Ratio	5.25
Current Ratio	5.56
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	1.55
EPS next Y	1.77
EPS next Q	0.43
EPS this Y	7.99%
EPS next Y	-8.03%
EPS next 5Y	3.06%
EPS past 3/5Y	- -
Sales past 3/5Y	20.37% 34.50%
EPS Y/Y TTM	323.64%
Sales Y/Y TTM	17.50%
EPS Q/Q	58.27%
Sales Q/Q	15.08%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	24.39% 3.14%

Insider Own	1.83%
Insider Trans	-15.47%
Inst Own	115.58%
Inst Trans	3.13%
ROA	8.63%
ROE	9.43%
ROIC	8.65%
Gross Margin	71.65%
Oper. Margin	15.76%
Profit Margin	21.80%
SMA20	-47.77%
SMA50	-46.06%
SMA200	-44.01%
Trades

Shs Outstand	80.39M
Shs Float	78.92M
Short Float	12.44%
Short Ratio	7.59
Short Interest	9.82M
52W High	60.91 -60.60%
52W Low	29.45 -18.52%
Volatility	4.75% 4.97%
ATR (14)	4.48
RSI (14)	24.51
Beta	1.96
Rel Volume	11.56
Avg Volume	1.29M
Volume	14,973,306

Perf Week	-54.00%
Perf Month	-44.39%
Perf Quarter	-49.17%
Perf Half Y	-41.12%
Perf YTD	-42.99%
Perf Year	-47.87%
Perf 3Y	-1.88%
Perf 5Y	-51.96%
Perf 10Y	282.17%
Recom	1.31
Target Price	54.91
Prev Close	52.52
Price	24.00
Change %	-54.30%

Consensus

Strong Buy

Avg. Price Target

$54.91

Implied Upside

+128.8%

Analysts16incl. previous ratings

Rating Distribution10 Buy · 5 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Today	Downgrade	LLeerink Partners	Outperform → Market Perform	$35	+45.8%
Jul 15, 2026	Initiated	PPiper Sandler	Overweight	$66	+175.0%
Jun 02, 2026	Resumed	WWolfe Research	Outperform	$55	+129.2%
Apr 13, 2026	Initiated	JJefferies	Buy	$45	+87.5%
Dec 02, 2025	Resumed	MMorgan Stanley	Underweight	$48	+100.0%
Oct 20, 2025	Initiated	CCanaccord Genuity	Hold	$40	+66.7%
Mar 20, 2025	Initiated	CCraig Hallum	Buy	$45	+87.5%
Dec 05, 2024	Downgrade	GGoldman	Buy → Neutral	$38 → $37	+54.2%
Nov 15, 2024	Initiated	WWolfe Research	Outperform	$50	+108.3%
Oct 16, 2024	Initiated	UUBS	Buy	$43	+79.2%
Oct 10, 2024	Initiated	GGuggenheim	Buy	$40	+66.7%
Feb 23, 2024	Reiterated	NNeedham	Buy	$30 → $33	+37.5%
Jan 18, 2023	Downgrade	RRaymond James	Outperform → Mkt Perform
Jan 05, 2023	Initiated	BScotiabank	Sector Outperform	$33	+37.5%
Jan 07, 2022	Initiated	SStephens	Overweight	$52	+116.7%
Nov 18, 2021	Resumed	GGoldman	Buy	$60	+150.0%
Jun 15, 2021	Initiated	RRaymond James	Outperform	$45	+87.5%
Feb 18, 2021	Resumed	NNeedham	Buy	$88	+266.7%
Jan 28, 2021	Initiated	TTruist	Buy	$61	+154.2%
Nov 10, 2020	Initiated	KKeyBanc Capital Markets	Sector Weight	$48	+100.0%

Today 09:28AM	Veracyte Crashes Almost 40% On Seismic Shift For Its Best-Selling Test (Investor's Business Daily) -54.30%
Nov-04-26 07:21PM	Veracyte Matches The Whisper, But A Decipher Reset And A Soft 2027 Preview Overshadow The Quarter (Earnings Whispers)
05:47PM	Veracyte: Q3 Earnings Snapshot (Associated Press)
04:05PM	Veracyte Announces Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-02-26 09:00AM	Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026 (GlobeNewswire)
04:05PM	Loading…
Oct-29-26 04:05PM	Veracyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-26 08:24PM	Veracyte's Third Raise Meets A Skeptical Crowd As Prosigna Launch Faces First Test (Earnings Whispers)
Oct-23-26 04:00AM	Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer (GlobeNewswire)
Oct-19-26 08:00AM	Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 (GlobeNewswire)
Oct-16-26 09:15AM	Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test (GlobeNewswire)
Oct-14-26 04:05PM	Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
Oct-06-26 08:16AM	Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies Unloads $18M Worth Of TWST Shares (Stocktwits) -6.34%
Sep-29-26 08:00AM	Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation (GlobeNewswire)
Sep-28-26 03:11PM	Cathie Wood Makes $64 Million Bet on Two Stocks (GuruFocus.com)
Sep-25-26 05:12PM	Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 (GlobeNewswire) -6.41%
07:10AM	Loading…
Sep-22-26 07:10AM	Beyond Meta, Cathie Woods ARKG Loads Up On These 4 Biotech Names (Stocktwits)
Sep-14-26 04:05PM	Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform (GlobeNewswire)
Sep-01-26 04:05PM	Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Jul-31-26 01:03AM	Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ... (GuruFocus.com) -22.52%
Jul-30-26 04:40PM	Veracyte: Q2 Earnings Snapshot (Associated Press) +7.31%
04:05PM	Veracyte Announces Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 04:05PM	Veracyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-16-26 08:13AM	Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It's Entering the U.S. (TSXV: SEGN) (FinanceWire)
Jul-09-26 04:05PM	Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 (Business Wire) +5.67%
Jun-18-26 04:09PM	This Top Stock Has Surged. CEO Explains Key To Veracyte's Success. (Investor's Business Daily)
May-30-26 08:00AM	ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer (Business Wire)
May-29-26 03:15PM	Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracytes Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy (Business Wire)
May-22-26 08:00AM	Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings (Business Wire)
May-21-26 06:00PM	OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer (Business Wire)
May-19-26 04:05PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire) +8.40%
09:00AM	Loading…
May-15-26 09:00AM	Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer (Business Wire)
May-11-26 11:45AM	Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors (Quartz)
May-05-26 05:09PM	Veracyte: Q1 Earnings Snapshot (Associated Press) +24.93%
04:05PM	Veracyte Announces First Quarter 2026 Financial Results (Business Wire)
Apr-28-26 09:00AM	Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers (Business Wire)
Apr-14-26 04:05PM	Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 (Business Wire) +5.73%
Mar-16-26 04:15PM	Veracyte Names Kevin Haas as Chief Development and Technology Officer (Business Wire)
Mar-02-26 12:59PM	OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis (Zacks)
Feb-27-26 12:37PM	GEHC & UCSF Form 10-Year Alliance to Advance Imaging & Care Delivery (Zacks) -5.57%
Feb-26-26 11:46AM	GEHC Unveils AI LOGIQ Ultrasound Systems to Boost Imaging & Workflow (Zacks) +8.48%
11:22AM	Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises (Zacks)
04:32AM	Veracyte Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Veracyte Inc (VCYT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-25-26 08:05PM	Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:37PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
01:55PM	Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand (Zacks)
01:55PM	FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand (Zacks)
11:57AM	Stryker Launches Synchfix EVT for Flexible Syndesmotic Fixation (Zacks)
Feb-24-26 12:40PM	BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy (Zacks)
09:40AM	AxoGen (AXGN) Q4 Earnings Miss Estimates (Zacks)
09:00AM	Veracyte to Highlight Extensive Decipher Data at 2026 ASCO GU Symposium (Business Wire)
Feb-23-26 12:42PM	ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation (Zacks)
09:45AM	Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
09:25AM	Does Veracyte (VCYT) Offer Both Strength and Opportunity? (Insider Monkey)
Feb-20-26 12:22PM	GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio (Zacks)
11:44AM	ITGR Shares Down Despite Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-19-26 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
11:05AM	Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal (Zacks)
Feb-18-26 01:09PM	GEHC Expands BARDA Collaboration With $35M Boost for AI Ultrasound (Zacks)
10:53AM	Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook (Zacks)
10:39AM	Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? (Zacks)
Feb-17-26 10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
09:19AM	Henry Schein Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-16-26 08:59AM	NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro (Zacks)
08:54AM	Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings (Zacks)
Feb-15-26 08:42AM	UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue (Insider Monkey)
Feb-13-26 09:39AM	Here's How Charles River Stock Is Placed Ahead of Q4 Earnings (Zacks)
08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Feb-11-26 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks)
Feb-10-26 12:20PM	GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency (Zacks)
11:22AM	Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth? (Zacks)
08:57AM	Labcorp's Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks)
10:40AM	GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration (Zacks)
08:02AM	Strength in Cardiovascular Unit Likely to Lift MDT's Q3 Performance (Zacks)
Feb-06-26 09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 05:40PM	Mettler-Toledo (MTD) Q4 Earnings and Revenues Beat Estimates (Zacks)
12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
09:35AM	Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-04-26 05:15PM	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
12:51PM	Here's Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
10:23AM	Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:47AM	Will Pharmacy and Consumer Wellness Segment Lead CVS' Q4 Earnings? (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
11:38AM	Zimmer Biomet to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
09:13AM	Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings? (Zacks)
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
09:55AM	Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:28AM	HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
08:02AM	Here's How Align Technology Is Placed Ahead of Q4 Earnings (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holstein Jens	Director	Sep 24 '26	Option Exercise	35.30	7,500	264,750	34,971	Oct 28 04:05 PM
Holstein Jens	Director	Oct 27 '26	Option Exercise	35.30	7,500	264,750	34,971	Oct 28 04:05 PM
Holstein Jens	Director	Oct 27 '26	Sale	50.00	7,500	375,000	27,471	Oct 28 04:05 PM
Holstein Jens	Director	Sep 24 '26	Sale	47.00	7,500	352,500	27,471	Oct 28 04:05 PM
EASTHAM KARIN	Director	Oct 27 '26	Option Exercise	27.01	10,000	270,100	25,097	Oct 28 04:05 PM
EASTHAM KARIN	Director	Oct 27 '26	Sale	50.00	14,850	742,573	10,247	Oct 28 04:05 PM
KARIN EASTHAM	Director	Oct 27 '26	Proposed Sale	48.20	14,850	715,770		Oct 27 04:30 PM
JENS HOLSTEIN	Director	Oct 27 '26	Proposed Sale	50.00	7,500	375,000		Oct 27 04:06 PM
Bhanji Muna	Director	Oct 19 '26	Sale	43.70	1,864	81,457	40,854	Oct 20 04:10 PM
JENS HOLSTEIN	Director	Sep 24 '26	Proposed Sale	47.00	7,500	352,500		Sep 24 04:25 PM
Leite John	Global Chief Commercial Off	Sep 21 '26	Sale	40.00	4,015	160,600	124,329	Sep 22 05:16 PM
JOHN LEITE	Officer	Sep 21 '26	Proposed Sale	39.80	4,015	159,777		Sep 21 04:31 PM
Holstein Jens	Director	Sep 14 '26	Sale	40.95	5,000	204,747	27,471	Sep 16 04:08 PM
JENS HOLSTEIN	Director	Sep 14 '26	Proposed Sale	40.95	5,000	204,747		Sep 14 05:00 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Sep 04 '26	Sale	43.05	13,110	564,410	133,048	Sep 04 07:54 PM
Chambers Rebecca	Chief Financial Officer	Sep 04 '26	Sale	43.10	3,652	157,394	166,025	Sep 04 07:54 PM
McGuire Annie	EVP, General Counsel	Sep 04 '26	Sale	43.09	3,254	140,212	131,160	Sep 04 07:54 PM
ANN MCGUIRE	Officer	Sep 04 '26	Proposed Sale	44.67	3,254	145,356		Sep 04 04:33 PM
REBECCA CHAMBERS	Officer	Sep 04 '26	Proposed Sale	44.67	3,652	163,135		Sep 04 04:33 PM
PHILLIP FEBBO	Officer	Sep 04 '26	Proposed Sale	44.67	13,110	585,624		Sep 04 04:28 PM
Bhanji Muna	Director	Sep 01 '26	Sale	42.97	1,864	80,096	42,718	Sep 03 04:48 PM
MUNA BHANJI	Director	Sep 01 '26	Proposed Sale	43.19	3,728	161,012		Sep 01 04:42 PM
EASTHAM KARIN	Director	Jun 18 '26	Sale	52.89	3,729	197,234	15,097	Jun 22 04:30 PM
KARIN EASTHAM	Director	Jun 18 '26	Proposed Sale	51.29	3,729	191,260		Jun 18 04:23 PM
McGuire Annie	EVP, General Counsel	Jun 04 '26	Sale	49.76	3,176	158,036	137,240	Jun 04 09:38 PM
Chambers Rebecca	Chief Financial Officer	Jun 04 '26	Sale	49.73	3,561	177,083	173,280	Jun 04 09:38 PM
Stapley Marc	Chief Executive Officer	Jun 04 '26	Option Exercise	36.60	138,051	5,052,667	578,545	Jun 04 09:38 PM
Stapley Marc	Chief Executive Officer	Jun 04 '26	Sale	50.12	138,051	6,919,585	440,494	Jun 04 09:38 PM
Leite John	Global Chief Commercial Off	Jun 04 '26	Sale	50.07	13,975	699,732	132,305	Jun 04 09:38 PM
ANN MCGUIRE	Officer	Jun 04 '26	Proposed Sale	48.69	3,176	154,639		Jun 04 04:32 PM
John Leite	Officer	Jun 04 '26	Proposed Sale	48.69	13,975	680,443		Jun 04 04:31 PM
MARC STAPLEY	Director	Jun 04 '26	Proposed Sale	48.69	138,051	6,721,703		Jun 04 04:31 PM
REBECCA CHAMBERS	Officer	Jun 04 '26	Proposed Sale	48.69	3,561	173,385		Jun 04 04:30 PM
Wygant Jonathan	VP, Chief Accounting Officer	May 22 '26	Option Exercise	24.80	24,000	595,200	69,434	May 27 04:19 PM
Wygant Jonathan	VP, Chief Accounting Officer	May 22 '26	Sale	45.40	24,000	1,089,624	45,434	May 27 04:19 PM
EPSTEIN ROBERT S	Director	May 20 '26	Sale	44.01	10,000	440,129	52,446	May 22 04:39 PM
ROBERT EPSTEIN	Director	May 20 '26	Proposed Sale	41.69	10,000	416,900		May 20 04:38 PM
McGuire Annie	SVP, General Counsel	May 06 '26	Sale	39.02	10,204	398,211	143,708	May 08 04:25 PM
ANN MCGUIRE	Officer	May 06 '26	Proposed Sale	32.97	10,204	336,426		May 06 04:25 PM
Chambers Rebecca	Chief Financial Officer	Mar 04 '26	Sale	36.14	18,341	662,869	131,196	Mar 06 04:33 PM
Stapley Marc	Chief Executive Officer	Mar 04 '26	Sale	35.97	45,523	1,637,594	357,554	Mar 06 04:32 PM
Leite John	Chief Commercial Officer-CLIA	Mar 04 '26	Sale	35.19	5,260	185,083	107,580	Mar 06 04:32 PM
McGuire Annie	SVP, General Counsel	Mar 04 '26	Sale	35.55	6,658	236,725	94,706	Mar 06 04:32 PM
ANN MCGUIRE	Officer	Mar 04 '26	Proposed Sale	35.08	6,658	233,563		Mar 04 04:42 PM
John Leite	Officer	Mar 04 '26	Proposed Sale	35.08	5,260	184,521		Mar 04 04:41 PM
REBECCA CHAMBERS	Officer	Mar 04 '26	Proposed Sale	35.08	18,341	643,402		Mar 04 04:40 PM
MARC STAPLEY	Director	Mar 04 '26	Proposed Sale	35.08	45,523	1,596,947		Mar 04 04:37 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Mar 02 '26	Sale	36.16	13,425	485,429	117,346	Mar 04 04:16 PM
PHILLIP FEBBO	Officer	Mar 02 '26	Proposed Sale	36.59	13,425	491,221		Mar 02 04:38 PM
McGuire Annie	SVP, General Counsel	Dec 16 '25	Sale	43.13	10,739	463,204	67,760	Dec 17 04:35 PM
ANN MCGUIRE	Officer	Dec 16 '25	Proposed Sale	43.53	10,739	467,469		Dec 16 04:30 PM
EASTHAM KARIN	Director	Dec 05 '25	Option Exercise	7.77	20,000	155,400	33,554	Dec 08 04:34 PM
EASTHAM KARIN	Director	Dec 05 '25	Sale	45.45	20,000	908,923	13,554	Dec 08 04:34 PM
KARIN EASTHAM	Director	Dec 05 '25	Proposed Sale	47.41	20,000	948,200		Dec 05 04:26 PM
McGuire Annie	SVP, General Counsel	Dec 04 '25	Sale	47.30	1,422	67,261	78,499	Dec 04 07:44 PM
Chambers Rebecca	Chief Financial Officer	Dec 04 '25	Sale	46.84	13,278	621,955	109,496	Dec 04 07:44 PM
Stapley Marc	Chief Executive Officer	Dec 04 '25	Sale	47.09	7,668	361,076	318,603	Dec 04 07:44 PM
Leite John	Chief Commercial Officer-CLIA	Dec 04 '25	Sale	47.51	1,278	60,718	82,113	Dec 04 07:43 PM
ANN MCGUIRE	Officer	Dec 04 '25	Proposed Sale	47.75	1,422	67,900		Dec 04 04:39 PM
REBECCA CHAMBERS	Officer	Dec 04 '25	Proposed Sale	47.75	13,278	634,024		Dec 04 04:39 PM
MARC STAPLEY	Director	Dec 04 '25	Proposed Sale	47.75	7,668	366,147		Dec 04 04:38 PM
Leite John	Chief Commercial Officer-CLIA	Nov 25 '25	Sale	50.00	2,808	140,400	86,291	Nov 26 04:27 PM
JONES EVAN/ FA	Director	Nov 25 '25	Sale	50.25	1,106	55,576	29,362	Nov 26 04:27 PM
Evan Jones	Director	Nov 25 '25	Proposed Sale	49.38	5,000	246,900		Nov 25 07:25 PM
John Leite	Officer	Nov 25 '25	Proposed Sale	46.70	4,086	190,816		Nov 25 04:28 PM
Holstein Jens	Director	Nov 20 '25	Sale	42.36	10,000	423,563	27,199	Nov 21 04:19 PM
JENS HOLSTEIN	Director	Nov 20 '25	Proposed Sale	42.36	10,000	423,563		Nov 20 04:03 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 07 '25	Sale	40.21	5,818	233,929	43,847	Nov 12 04:25 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 10 '25	Sale	42.33	5,102	215,978	38,745	Nov 12 04:25 PM

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

CEO & DirectorMr. Marc A. Stapley

Executive VP & CFOMs. Rebecca Chambers

Chief Scientific & Medical OfficerDr. Phillip G. Febbo M.D.

Executive VPMs. Annie McGuire

Global Chief Commercial OfficerDr. John Leite Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCYT

Veracyte Inc

Upgrade your Finviz experience